Harvard Bioscience Elects New Board Chairman

Harvard Bioscience Inc., a global developer, manufacturer and marketer of solutions to advance life science, has elected James Green, a current board member, as the new chairman of its Board of Directors effective June 5. He replaces Earl R. Lewis, who has served as chairman since July 2013 and has been a board member since 2000.
 
“It is an honor to be named chairman of Harvard Bioscience and I look forward to this expanded role,” Green said. “As a member of the board for the past two years, I have seen the executive team build a more effective operation while navigating a difficult market environment, and feel the team is poised to deliver shareholder value through expanding profitable growth.”           
 
Green was appointed a director of the company on April 30, 2015. He is the former president and CEO of Analogic Corporation, a publicly held advanced medical and security imaging company; he served in that position from 2007 to 2016. From 2005 to 2007, Green was regional vice president of the California division of Quest Diagnostics Corporation, successfully integrating the full Unilab sales and operations into the national laboratory network of Quest Diagnostics. From 1983 to 2005, he worked in various senior leadership positions at Koninklijke Philips Electronics N.V., St. Jude Medical Inc., Beckman Instruments, McDonnell Douglas Corporation and Northrop Advanced Systems. Green has a bachelor of science degree in electrical engineering from the University of Missouri at Columbia, a master’s degree in computer engineering from the University of Southern California, and is a graduate of the Stanford University Executive Program.

“James Green has been a valuable member of the board since he joined two years ago,” said Jeffrey Duchemin, President and CEO of Harvard Bioscience. “He brings a tremendous amount of experience having been involved in global businesses that span the laboratory, instrumentation and technology sectors.  We are honored to have James Green lead our board as we continue to execute our strategy.  At the same time, we are extremely grateful that Earl Lewis, who has served as a board member for 17 years, including chairman for the past four years, will continue to contribute his knowledge, industry experience and insight to the company.”
 
Harvard Bioscience is a global developer, manufacturer and marketer of solutions to advance life science. Its products are sold to researchers in over 100 countries through its global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. The company has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada, and China.